Investor & Media
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid’s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. In August 2018, Ovid announced that STARS, an international, double-blind, placebo-controlled, randomized Phase 2 clinical trial in adults and adolescents with Angelman syndrome, met its primary endpoint of safety and tolerability.